[HTML][HTML] The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers
S Jafari, H Motedayyen, P Javadi, K Jamali… - Frontiers in …, 2024 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is among the most penetrative malignancies
affecting humans, with mounting incidence prevalence worldwide. This cancer is usually not …
affecting humans, with mounting incidence prevalence worldwide. This cancer is usually not …
The role of AMPK in pancreatic cancer: from carcinogenesis to treatment
S Shahrokhi Nejad, S Razi, N Rezaei - Clinical and Translational …, 2024 - Springer
Pancreatic cancer has doubled over the previous two decades. Routine therapies are
becoming incredibly resistant and failing to compensate for the burden caused by this …
becoming incredibly resistant and failing to compensate for the burden caused by this …
Emerging Therapeutic Options in Pancreatic Cancer Management
D Delle Cave - International Journal of Molecular Sciences, 2024 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival
rate of< 8%[1–3]. PDAC is characterized by dense desmoplastic stroma, which can …
rate of< 8%[1–3]. PDAC is characterized by dense desmoplastic stroma, which can …
Emerging Therapeutic Options in Pancreatic Cancer Management
D Delle Cave - Int. J. Mol. Sci - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival
rate of< 8%[1–3]. PDAC is characterized by dense desmoplastic stroma, which can …
rate of< 8%[1–3]. PDAC is characterized by dense desmoplastic stroma, which can …